Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | LIN28A | Q9H9Z2 | 1/20 | 0.70 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29877048 | 0.96 | TDP1 (0.70) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL8604224 | 0.96 | TDP1 (0.70) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL12338697 | 0.92 | TDP1 (0.78) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL6864949 | 0.90 | TDP1 (0.81) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL138261 | 0.87 | SMN1; SMN2 (0.83) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL11471516 | 0.86 | TDP1 (0.62) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL16215876 | 0.86 | TDP1 (0.58) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL13555816 | 0.86 | TDP1 (0.62) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL15483659 | 0.85 | TDP1 (0.53) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 | |
| SCHEMBL13555815 | 0.85 | MAPT (0.53) | TDP1MAPTSMN1; SMN2LIN28AKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302409-A1 | DETERMINING PANCREAS DISEASE USING FUNCTIONAL IMAGING | HEPATIQ, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3426740-B1 | METHOD OF PREPARING AN OXIDATIVELY CURABLE COATING FORMULATION | MILLIKEN INDUSTRIALS LTD (GB) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023279211-A1 | METAL-CONTAINING POLYMERS FOR MASS CYTOMETRY | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2023-01-12 | — | — | WO | disclosed |
| US-11512222-B2 | Method of preparing an oxidatively curable coating formulation | BORCHERS GMBH (DE) | 2022-11-29 | — | — | US | disclosed |
| CN-114525071-A | Method for producing coating formulations curable by oxidation | 美利肯工业有限公司 | 2022-05-24 | — | — | CN | disclosed |
| EP-3978488-A1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | Universitetet I Oslo (NO) | 2022-04-06 | — | — | EP | disclosed |
| EP-3497095-B1 | ZINC CHELATING COMPOUNDS FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | UNIV OSLO (NO) | 2021-07-14 | — | — | EP | disclosed |
| US-10981866-B2 | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200384115-A1 | TARGETED DELIVERY TO BETA CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-10 | — | — | US | disclosed |
| US-20200231543-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-07-23 | — | — | US | disclosed |
| US-8211401-B2 | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120070378-A1 | LANTHANIDE ION COMPLEXES AND IMAGING METHOD | THE UNIVERSITY OF AKRON (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120070378-A1 | LANTHANIDE ION COMPLEXES AND IMAGING METHOD | THE UNIVERSITY OF AKRON (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110243857-A1 | SMART CONTRAST AGENTS FOR MRI IMAGING | UNIVERSITE DE ROUEN (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20110243857-A1 | SMART CONTRAST AGENTS FOR MRI IMAGING | UNIVERSITE DE ROUEN (FR) | 2011-10-06 | — | — | US | disclosed |
| US-20100298270-A1 | Novel Compounds and Methods of Using Them | SYNDAX PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2010075003-A1 | LANTHANIDE ION COMPLEXES AND IMAGING METHOD | THE UNIVERSITY OF AKRON (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | MOLECULAR INSIGHT PHARMACEUTICALS, INC. | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200384115-A1 | TARGETED DELIVERY TO BETA CELLS | IAPP, ZFR, ZC3H11A | TDP1 2688/4885MAPT 1712/4885SMN1; SMN2 1727/4885 |
| US-20100178246-A1 | TECHNETIUM- AND RHENIUM-BIS(HETEROARYL) COMPLEXES AND METHODS OF USE THEREOF FOR INHIBITING PSMA | PSMA1, PSMA5, PSMA3 | TDP1 3443/4885MAPT 811/4885SMN1; SMN2 3915/4885 |
| US-20110243857-A1 | SMART CONTRAST AGENTS FOR MRI IMAGING | CALCOCO2, COIL, CDR2 | TDP1 4503/4885MAPT 1148/4885SMN1; SMN2 524/4885 |
| US-20100298270-A1 | Novel Compounds and Methods of Using Them | HDAC1, HDAC3, HDAC6 | TDP1 1085/4885MAPT 2078/4885SMN1; SMN2 430/4885 |
| US-10981866-B2 | Chemical conjugates of Evans Blue derivatives and their use as radiotherapy and imaging agents | RABL3, H1-4, SSTR3 | TDP1 4069/4885MAPT 1099/4885SMN1; SMN2 501/4885 |
| US-20100098633-A1 | SELECTIVE SEPRASE INHIBITORS | SLC6A7, DNPEP, PREP | TDP1 3266/4885MAPT 1542/4885SMN1; SMN2 1942/4885 |
| US-20090175794-A1 | INHIBITORS OF CARBONIC ANHYDRASE IX | CA9, CA12, CA1 | TDP1 3377/4885MAPT 3380/4885SMN1; SMN2 3298/4885 |
| US-20120070378-A1 | LANTHANIDE ION COMPLEXES AND IMAGING METHOD | INSR, KCNH3, CA9 | TDP1 4543/4885MAPT 1478/4885SMN1; SMN2 4387/4885 |
| US-20200231543-A1 | CHEMICAL CONJUGATES OF EVANS BLUE DERIVATIVES AND THEIR USE AS RADIOTHERAPY AND IMAGING AGENTS | RABL3, H1-4, SSTR3 | TDP1 4069/4885MAPT 1099/4885SMN1; SMN2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.